PL444395A1 - 1-(1-aryloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie - Google Patents

1-(1-aryloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie

Info

Publication number
PL444395A1
PL444395A1 PL444395A PL44439523A PL444395A1 PL 444395 A1 PL444395 A1 PL 444395A1 PL 444395 A PL444395 A PL 444395A PL 44439523 A PL44439523 A PL 44439523A PL 444395 A1 PL444395 A1 PL 444395A1
Authority
PL
Poland
Prior art keywords
arylimidazolin
urea derivatives
production method
arylalkyl urea
arylalkyl
Prior art date
Application number
PL444395A
Other languages
English (en)
Other versions
PL248268B1 (pl
Inventor
Dariusz Matosiuk
Dominik Straszak
Sylwia Woźniak
Original Assignee
Uniwersytet Medyczny W Lublinie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Lublinie filed Critical Uniwersytet Medyczny W Lublinie
Priority to PL444395A priority Critical patent/PL248268B1/pl
Publication of PL444395A1 publication Critical patent/PL444395A1/pl
Publication of PL248268B1 publication Critical patent/PL248268B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia są 1-(1-aryloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie w leczeniu bólu neuropatycznego i przewlekłego.
PL444395A 2023-04-13 2023-04-13 1-(1-fenyloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie PL248268B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL444395A PL248268B1 (pl) 2023-04-13 2023-04-13 1-(1-fenyloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444395A PL248268B1 (pl) 2023-04-13 2023-04-13 1-(1-fenyloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie

Publications (2)

Publication Number Publication Date
PL444395A1 true PL444395A1 (pl) 2024-10-14
PL248268B1 PL248268B1 (pl) 2025-11-17

Family

ID=93062646

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444395A PL248268B1 (pl) 2023-04-13 2023-04-13 1-(1-fenyloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie

Country Status (1)

Country Link
PL (1) PL248268B1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8793082A (en) * 1981-09-03 1983-03-10 Hoechst A.G. Urea derivatives
WO1996010559A1 (en) * 1994-10-04 1996-04-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
WO2001036403A1 (en) * 1999-11-16 2001-05-25 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
EP1170288A2 (fr) * 2000-06-29 2002-01-09 Les Laboratoires Servier Dérivés de diphenylurée et leur utilisation en tant qu'antagonistes alpha2/5-HT2c

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8793082A (en) * 1981-09-03 1983-03-10 Hoechst A.G. Urea derivatives
WO1996010559A1 (en) * 1994-10-04 1996-04-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
WO2001036403A1 (en) * 1999-11-16 2001-05-25 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
EP1170288A2 (fr) * 2000-06-29 2002-01-09 Les Laboratoires Servier Dérivés de diphenylurée et leur utilisation en tant qu'antagonistes alpha2/5-HT2c

Also Published As

Publication number Publication date
PL248268B1 (pl) 2025-11-17

Similar Documents

Publication Publication Date Title
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
JOP20240223A1 (ar) معالجات سرطان باستخدام مثبطات prmt5 بالتعاون مع mta
JOP20240210A1 (ar) مثبطات kras
IL287728A (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
WO2011127188A3 (en) Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
MX2023014435A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
JOP20240237A1 (ar) مركبات أريل غير متجانسة لمعالجة الألم
JOP20240235A1 (ar) مركبات أريل غير متجانسة لمعالجة الألم
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
IL299700A (en) Kcnt1 inhibitors and methods of use
MX2023006542A (es) Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
IL320848A (en) RIPK2 inhibitors and their medical uses
EP4507650A4 (en) MASSAGE AND PRESSURE RELEASE TOOL
MX2023003583A (es) Forma cristalina del compuesto de piridinilfenilo y metodo de preparacion del mismo.
EP4375270A4 (en) SUPRAMOLECULAR AMINO ACID OR SALT THEREOF, ITS PREPARATION PROCESS AND ITS USE
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
JOP20220319B1 (ar) أزيلاستين كعلاج مضاد للفيروسات
JOP20250074A1 (ar) تركيبة دالبافانسين سائلة
AR114147A1 (es) Uso tópico y entrega de microorganismos oxidantes de amoníaco
MX2022014109A (es) Uso de compuestos para el tratamiento de infecciones virales.
JOP20240156A1 (ar) طريقة لعلاج الداء النشواني al
MX2023015147A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
EP4514812A4 (en) TREATMENT OF GM1 DEFICIENCIES